Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tracleer bosentan: Phase III; marketed to treat pulmonary arterial hypertension

Long-term 36-month follow-up data from 169 patients in 2 international Phase III trials (Breathe 1 and study 351)

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE